Skip to main content
OpenTrials
Completed

NCT Number: NCT07367555

Effect Of Sodium Glucose Co-Transporter-2 (SGLT-2) Inhibitors on Body Mass Index After 3 Months of Use in Diabetic Patients

Total of 360 participants were enrolled and prescribed oral 200 mg SGLT-2 tablet. All participants were followed-up for about three months. Body mass index was measured before and after three months and mean change in BMI was assessed.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Diabete Mellitus Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

30 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

CMH Multan

Multan, Punjab Province, 60010, Pakistan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Individuals diagnosed with type II diabetes mellitus ( blood sugar level (random) at presentation was above 186 mg/dl and HbA1c was more than 6.5% on laboratory investigations)

Exclusion criteria

  • Individuals already taking trail drug or any other anti-glycemic drug or insulin for >6 months

Treatment and study plan

Oral 100 gram Empagliflozin tablet along with diet plan and exercise

Drug

oral 100 gram Empagliflozin tablet along with diet plan and exercise

Diet plan and exercise

Other

Only Life style modification was advised. Changes in BMI were assessed.

Primary outcomes

  1. Weight

    Time frame: 03 Months

    Weight is measured in Kilograms

Secondary outcomes

  1. Height

    Time frame: 03 months

    Height is measured in meters

Sponsors and collaborators

Lead sponsor

Ariba Shafiq

Other

Registry information

Official study title

Effect Of Sodium Glucose Co-Transporter-2 (SGLT-2) Inhibitors on Body Mass Index After 3 Months of Use in Diabetic Patients"

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Jan 26, 2026
Registry last updated
Jan 26, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.